

Longevience AB

A company in the Milmed Unico AB group

Investment Case

January 2025




Living longer and healthier

Longevience AB is seeking €2.6M

To accelerate R&D and Sales. To build an organization for distribution of our first product: AgeViva



Aging is the major risk factor for chronic diseases: heart disease, cancer, Type 2 diabetes and neurodegenerative diseases



The longevity market is estimated to reach \$45B by 2028 at a CAGR of 22.2 %.



AgeViva is our innovative dietary supplement derived from yeast cells treated with electromagnetic millimeter wavelengths.



Several studies show AgeViva's effects on important hallmarks of Longevity, such as inflammation and autophagy



AgeViva is a science-based and natural product with a favorable safety profile



Longevience forecast a revenue + € 300k with a profit margin of 60% in 2029

AgeViva promotes anti-aging and longevity

- A cutting-edge dietary supplement from yeast cells
- Reduces inflammation and oxidative stress
- Supports brain and nerve growth factors
- It has Anti-parkinsonian effects



Sources: Longevience Yeast Alters the LPS-Induced M1 Microglia Cells to Form M2 Anti-Inflammatory Phenotype [Link](#)

We aim to reach the global market for longevity products

- Longevity is of interest for the traditional pharma industry.
- The longevity market estimates an annual growth rate (CAGR) of 22.2 %.
- The combined markets for Longevity and diseases such as Type 2 diabetes that can be treated with longevity drugs was \$127B in 2021.

\$4.2B

2023 Global anti-ageing supplement market

\$20.3B

Longevity market estimation in 2024


\$45B

Market size in 2028 at a CAGR of 22.2 %

€2.6M is needed to accelerate R&D and sales and build an organization fit for purpose

Use of proceeds in two tranches – Q1 2025 and Q1 2026

- **IP:** Trademark filed for AgeViva and Longevience and patent filed in Sales markets in 2025.
- **Marketing:** Attend one partnering conference per month
- **Organization:** Recruit 5 FTEs in 2025 (CEO, sales rep, 2x admin, distribution) and 3 FTEs in 2026 (Scientific officer, IT, CFO). 2 more sales reps in 2027 and 2028.
- **Sales:** During H1 2025: Start sales own webshop, Contact with 10 pot. distributors. Connecting with companies from BS market research and LOI with 3 distributors
- **R&D:** Research studies finalized. 7 in vivo and 17 in vitro studies focused on the hallmark of aging.



Board of Directors and Advisory Board

The board of directors offers exceptional expertise in aging research, global business development, and entrepreneurship – critical pillars in crafting a robust roadmap for Longevidence.

Their strengths are further enhanced by the deep insights of experienced advisors, complementing the profound expertise of Thomas Lenz, Prof. Trevor Archer, and Roger Karlsson.

- **Dr. Gosálbez** brings 10 years of expertise in microbiome technologies and regulatory intelligence, ensuring alignment with innovation and standards.
- **Dr. Schumacher** offers decades of experience in genetics and longevity, with pioneering work on aging and biomarkers.
- **Sara Nikman** has 14 years of life science industry experience, spanning preclinical to clinical research, quality work, and project management roles at companies like Merck, GSK, and Sanofi.
- **Prof. Businaro** provides expertise in immunology, inflammation, and Alzheimer’s disease, supporting biome-targeted health benefits.
- **Johan Olsson** has 25+ years in life sciences and valuation, corporate development, investments with success in fundraising and partnerships.

